Pharma IQ Members

Vaccines for the World
Contributor: Pharma IQ
Posted: 13/01/2017
Pharma IQ
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I Full Content »
Contributor: Chanice Henry
Posted: 15/03/2016
Miss Chanice Henry
On the route to creating new therapeutics for patients, pharma firms require access a range of diverse biological samples. However, one challenge for the market is locating collaborations that will provide a channel to diverse and high quality samples. This is mirrored by the intentions of both public biobanks and academic or hospital biobanks which have a strong focus on hosting and distributing good quality samples that are of high usability in the eyes of biopharma firms. Full Content »
Contributor: Dr Steven Bradshaw
Posted: 13/01/2017
Dr Steven Bradshaw
2017 is set to be an exciting time for pharma companies to develop and adopt new strategies and models to stay ahead of both the expected and unexpected market trends. Full Content »
Contributor: Chanice Henry
Posted: 22/12/2015
Chan
Pharma IQ presents the top content pieces for 2015 in this annual bumper, so you can browse through some of this year’s best articles to feature on the portal. Full Content »
Contributor: Chanice Henry
Posted: 15/03/2016
Miss Chanice Henry
On the route to creating new therapeutics for patients, pharma firms require access a range of diverse biological samples. However, one challenge for the market is locating collaborations that will provide a channel to diverse and high quality samples. This is mirrored by the intentions of both public biobanks and academic or hospital biobanks which have a strong focus on hosting and distributing good quality samples that are of high usability in the eyes of biopharma firms. Full Whitepaper »